Feasibility Trial of Pembrolizumab in Unresectable Thymoma and Thymic Carcinoma
Phase of Trial: Phase I
Latest Information Update: 02 Jan 2019
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Carcinoma; Malignant thymoma; Thymoma
- Focus Adverse reactions
- 06 Dec 2017 Planned End Date changed from 1 Mar 2020 to 1 Jun 2019.
- 06 Dec 2017 Planned primary completion date changed from 1 Mar 2020 to 1 Jun 2019.
- 06 Dec 2017 Status changed from not yet recruiting to recruiting.